Axsome Therapeutics, Inc (AXSM)
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for the treatment of central nervous system (CNS) disorders, including depression, migraine, and Parkinson's disease. The company aims to address unmet medical needs through novel proprietary compounds and formulations.
Company News
Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.
Law firm Johnson Fistel is investigating potential legal violations by officers of General Motors, DocGo, Estée Lauder, and Axsome Therapeutics, with class action lawsuits surviving motions to dismiss.
Teva Pharmaceutical and Biolojic Design announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP and IL-13, which can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma.
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Biotech stocks have been heavily impacted by rising interest rates and FTC challenges. Find out my investment strategy while selecting biotech names.
